Formycon AG (FRA:FYB)
23.10
-0.25 (-1.07%)
At close: Oct 23, 2025
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 51.78M, down -14.84% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
51.78M
Revenue Growth
-14.84%
P/S Ratio
7.88
Revenue / Employee
211.34K
Employees
250
Market Cap
408.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 35.89B |
| Deutsche Bank Aktiengesellschaft | 30.07B |
Formycon AG News
- 2 days ago - Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe - Nasdaq
- 3 days ago - EQS-News: Formycon’s FYB201/Ranivisio sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe - Wallstreet:Online
- 8 days ago - EQS-News: Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea biosimilar FYB203 (aflibercept) for Australia and Latin America - Wallstreet:Online
- 16 days ago - EQS-AFR: Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements - Wallstreet:Online
- 22 days ago - Formycon Reaches Settlement With Regeneron Over U.S. Eylea Biosimilar Patent Disputes - Nasdaq
- 22 days ago - EQS-News: Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron - Wallstreet:Online
- 23 days ago - EQS-NVR: Formycon AG: Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution - Wallstreet:Online
- 5 weeks ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista